Metacrine Inc

NASDAQ:MTCR   3:59:50 PM EDT
3.75
+0.03 (+0.81%)
Earnings Announcements

Metacrine Updates Met642 Clinical Development Milestone, Reports Q2 Results

Published: 08/12/2021 12:18 GMT
Metacrine Inc (MTCR) - Metacrine, Inc. - Believes It Has Sufficient Capital to Fund Its Current Operating Plan Through 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.